title: Antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor and of standard heparin in the rabbit.
abstract: This study reports on the anticoagulant, antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor (SDTI) in comparison with standard heparin (SH). The anticoagulant effect was determined with the thrombin clotting time (TCT) and the activated partial thromboplastin time (APTT). SDTI was more potent than SH in prolonging the TCT, but as potent as SH in prolonging the APTT. The antithrombotic effect was determined using a modified Wessler model in the rabbit, either 30 min after a continuous IV infusion of increasing doses or at various times after a single SC injection (20 mg/kg). After continuous IV infusion of 187 micrograms/kg/h of SDTI and of 60 micrograms/kg/h of SH, significant thrombus prevention effects were obtained (59 and 57% respectively). Increasing the dose of SDTI up to 3000 micrograms/kg/h did not significantly improve the antithrombotic effect. After SC injection, a significant antithrombotic effect was observed for 12 h with SDTI but for more than 24 h with SH. The bleeding effect was studied using the rabbit ear model 15 min after a continuous infusion of 7.5 and 15 mg/kg/h: the amounts of blood loss were dose-dependent and comparable for SDTI and SH. These studies also indicated that SDTI possesses a considerable shorter half-life in comparison with SH. Accordingly, the ex vivo concentrations generated after continuous IV infusion or SC injection of the same dose were higher for SH than for the SDTI.
authors: Laboratoire d' Hémostase, Centre de Transfusion Sanguine, Toulouse, France.
authors: Y
authors: Y
authors: Cadroy
authors: C
authors: C
authors: Caranobe
authors: A
authors: A
authors: Bernat
authors: J P
authors: JP
authors: Maffrand
authors: P
authors: P
authors: Sié
authors: B
authors: B
authors: Boneu
mesh_terms: D000818:Animals; D000991:Antithrombins / Q000008:administration & dosage / Q000494:pharmacology*; D004151:Dipeptides; D004353:Drug Evaluation, Preclinical; D006470:Hemorrhage / Q000139:chemically induced*; D006493:Heparin / Q000494:pharmacology; D066298:In Vitro Techniques; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D010314:Partial Thromboplastin Time; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D011817:Rabbits; D013918:Thrombin Time; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D000991:Antithrombins; D004151:Dipeptides; D010880:Piperidines; C038708:N(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide; D006493:Heparin